Search

Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled Trial

We conducted an open randomized controlled trial in Papua New Guinea to compare safety, immunogenicity and priming for memory of 7-valent PCV (PCV7) given in...

Association between early bacterial carriage and otitis media in Aboriginal and non-Aboriginal children

Streptococcus pneumoniae (Pnc), nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) are the most important bacterial pathogens...

Clinical Associate Professor Deborah Lehmann

Honorary Emeritus Fellow

Reflections and perceptions of chronic tinnitus during childhood

Reflections and perceptions of chronic tinnitus during childhood

Topical antiseptics for chronic suppurative otitis media

The effectiveness and safety profile of antiseptics in the treatment of chronic suppurative otitis media is uncertain

Cochrane corner: interventions to prevent hearing loss caused by noise at work

The aim of this Cochrane Review was to find out if hearing loss caused by noise at work is being prevented by current interventions

The epidemiological transition in Papua New Guinea: new evidence from verbal autopsy studies

Our results indicate immediate priorities for health service planning and for strengthening of vital registration systems

Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomised controlled trial of PCV in Papua New Guinean infants

Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting

Australian Aboriginal children have higher hospitalization rates for otitis media but lower surgical procedures than non-Aboriginal children

Aboriginal children and children from lower socio-economic backgrounds were over-represented with OM-related hospitalizations but had fewer TTIs

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate Vaccine

PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses